Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

Fig. 1

This study was divided into two parts: VEM1-IPI and VEM2. During VEM1-IPI, patients received VEM 960 mg twice daily for 6 weeks followed by IPI 10 mg/kg induction and maintenance therapy. During VEM2, patients who progressed after IPI received VEM at their previously tolerated dose (a). Among 70 patients who enrolled in this study, 46 were treated during VEM1 and continued to IPI induction. Eight patients received IPI maintenance therapy. Nineteen patients were treated during VEM2. Reasons for discontinuation of study drug are provided (b). AE = adverse event; BID = twice daily; IPI = ipilimumab; PO = by mouth; PD = progressive disease; Q3W = every 3 weeks; Q12W = every 12 weeks; VEM = vemurafenib

Back to article page